BDMD (Baird Medical Investment Holdings) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Baird Medical Investment Holdings ROE % Adjusted to Book Value?

Baird Medical Investment Holdings's ROE % for the quarter that ended in Dec. 2023 was 34.19%. Baird Medical Investment Holdings's PB Ratio for the quarter that ended in Dec. 2023 was N/A. Baird Medical Investment Holdings's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was N/A.

Baird Medical Investment Holdings ROE % Adjusted to Book Value Historical Data

The historical data trend for Baird Medical Investment Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baird Medical Investment Holdings ROE % Adjusted to Book Value Chart

Baird Medical Investment Holdings Annual Data

Trend

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Baird Medical Investment Holdings Semi-Annual Data
	Dec21	Dec22	Dec23
ROE % Adjusted to Book Value	-	-	-

Competitive Comparison of Baird Medical Investment Holdings's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Baird Medical Investment Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Baird Medical Investment Holdings's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Baird Medical Investment Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Baird Medical Investment Holdings's ROE % Adjusted to Book Value falls into.

Baird Medical Investment Holdings ROE % Adjusted to Book Value Calculation

Baird Medical Investment Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	34.19%	/	N/A
	=	N/A

Baird Medical Investment Holdings's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	34.19%	/	N/A
	=	N/A

Baird Medical Investment Holdings ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Baird Medical Investment Holdings's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Baird Medical Investment Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Baird Medical Investment Holdings Ltd (NAS:BDMD) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.15 Rongtong Street, Room 202, 2nd Floor, Baide Building, Building 11, Yuexiu, Guangzhou, CHN

Website

Baird Medical Investment Holdings Ltd is one of the microwave ablation medical device developers and providers in the PRC for minimally invasive treatment of tumors. Its proprietary medical devices are used for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast lumps. Microwave ablation is a minimally invasive treatment technique that denaturalizes and coagulates the protein of tumor cells with extreme heat generated by microwave energy. Microwave ablation treatments have been applied to benign and malignant tumors, and the company believes the products are safer, minimally invasive and easier to operate with faster recovery periods and lower complication rates for patients, as compared to traditional treatment methods.